Explore the possibilities of the new ZEISS METROTOM 800 320 kV

Free ZEISS webinar July 10, 9:00-9:45 AM and 5:00-5:45 PM.

Individual DNA passport could result in fewer drug side effects

You may be required to show a DNA passport when you pick up medicines at the pharmacy in the future. According to a new study, patients might suffer 30% fewer s...

Första läkemedlet mot förlossningsdepression får grönt ljus i EU

EU-kommissionen har för första gången godkänt ett läkemedel mot förlossningsdepression, närmare bestämt amerikanska Biogens Zurzuvae.

Her company is developing a new tablet form obesity drug

Obesity and diabetes are the primary targets of a new tablet treatment under development by Malmö-based Pila Pharma. The company’s ambition is to take on the bi...

Moderna fälls efter 20 000-kronorserbjudande till barn

Moderna kritiseras i Storbritannien för ett felaktigt meddelande där barn erbjöds 1 500 pund, motsvarande över 20 000 kronor, för deltagande i en klinisk studie...

Halsfluss i fokus när Magnus Gisslén ryter vidare

Magnus Gissléns sågning av Folkhälsomyndigheten (FHM) fortsätter och nu riktar han ljuset mot användning av antibiotika vid halsfluss. Han kritiserar också nätv...

The Future of Swedish & Danish Life Science (2026)

Icelandic pharmaceutical company Alvotech to list on Nasdaq Stockholm

One of Iceland's largest companies, the pharmaceutical firm Alvotech, has announced its intention to list on Nasdaq Stockholm.

ZEISS Smartzoom 100 for Inspection Efficiency

Catch up on our free webinar.

Caroline Leksell Cooke ny chef på Elekta

Elekta har rekryterat Caroline Leksell Cooke till ny Senior Vice President och Head of Neuro Solutions. Hon börjar sin nya tjänst den 1 november.

AstraZeneca´s Trixeo approved in the UK using propellant with near-zero Global Warming Potential

AstraZeneca has received approval in the United Kingdom for its inhaled respiratory medicine Trixeo Aerosphere with a new propellant that is reported to reduce ...

Svenska forskare fann ”mellanform av parkinson och alzheimer”

Vissa patienter som får diagnosen Parkinsons sjukdom kan i själva verket ha en annan sjukdom som snarare liknar alzheimer. Det enligt en ny studie från Umeå och...

Nobel Prize winner Torsten Wiesel turns 100: “Old men like me should use their experience to help the young”

In 1955, a young Torsten Wiesel jumped on a boat to the US and embarked on a fabulous career as a neuroscientist, crowned with a Nobel Prize for his work. Now 1...

Trump in new push to lower drug prices

U.S. President Donald Trump announced on Sunday that he plans to sign an executive order to lower the cost of prescription drugs to the same levels paid in othe...

Automated dispensing of a viscous hydrogel

A suitable solution developed for UPM Biomedicals In the Festo LifeTech Application Center we tested a setup for UPM Biomedicals for the automatic dispensing of...

Clean solutions - Handling viscose substances with precision

Laboratories in the chemical, petrochemical, pharmaceutical and food technology industries are increasingly relying on automation for sample preparation. The Mo...

Strömhopp från Novos styrelse – extra stämma utlyst

Större delen av styrelsen i danska läkemedelsjätten Novo Nordisk hoppar av efter oenighet med huvudägaren Novo Nordisk Foundation.

Business Sweden: “Companies have a lot to offer in data-driven precision medicine”

Data-driven precision medicine can potentially solve major healthcare problems, states Business Sweden in a new report on the subject.

Bredd och spets på välbesökt life science-event

Hela kedjan inom läkemedelsframställning – från den tidiga forskningen till fyllning av vialer – var representerad när konferensen New Horizons in Biologics & B...

Merck KGaA acquires American company in €3.0 billion deal

Germany’s Merck is completing the acquisition of Springwork Therapeutics for 3 billion euros.

Högteknologiska bolag allt mer intresserade av hälsa

Under många år har techföretag intresserat sig för hälso- och sjukvården och det intresset ser ut att öka. ”Det är inget plötsligt trendbrott, det handlar mer o...

Positive EMA Decision for BioArctic's New Drug Candidate

Bioarctic's drug candidate for multiple system atrophy, exidavnemab, is recommended to be classified as an orphan drug, according to the European Medicines Agency (EMA).

Mikael Kubista back with new venture after turbulent exit

Entrepreneur and researcher Mikael Kubista is starting a new company. Now he is also free to comment on the sequence of events that led to him losing ownership ...

Join our measuringhero Jay on the innovation tour

Experience our latest innovation from the Control fair.